Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Estradiol vaginal cream is a topical hormonal preparation containing 17β-estradiol, a naturally occurring human estrogen. Developed by Prasco LLC as a generic equivalent to Estrace®, this formulation is specifically indicated for the treatment of vulvar and vaginal atrophy (VVA) in postmenopausal women. The drug works by binding to and activating estrogen receptors (ERα and ERβ) in the vaginal tissues, which reverses the thinning and drying of the vaginal lining caused by declining estrogen levels during menopause. By restoring the vaginal epithelium and maintaining a healthy acidic pH, the cream alleviates symptoms such as vaginal dryness, itching, and dyspareunia (painful intercourse). Prasco conducted Phase 3 clinical trials to demonstrate the therapeutic equivalence of their 0.01% estradiol cream to the reference brand, ensuring comparable efficacy and safety profiles.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on estradiol vaginal cream.